Site networks now carry a growing share of research, and they are not all built the same way. These six questions get to how a network actually runs a study. We have answered each for Hawthorne Health.
1. How many agreements and budgets will this study need?
Each separate agreement is another budget and contract to settle before a site can activate. In WCG's 2025 survey, 73% of sites named budgets and contracts as the leading cause of start-up delays.
Our answer: one clinical trial agreement covers all our pharmacy-based community sites and our in-home visits.
2. Who is my single point of contact across all sites?
One project manager means one view of enrollment, issues and timelines, rather than one per site.
Our answer: one project manager across all our locations.
3. Do all sites work from the same SOPs and quality system?
Shared SOPs reduce variability between sites and make oversight simpler for the sponsor and the CRO.
Our answer: one set of SOPs and one quality system across our 9 pharmacy-based community sites and our in-home visits.
4. Who leads feasibility, and is it the same process at all sites?
A standard process means site estimates can be compared, not just collected.
Our answer: feasibility and start-up oversight are centrally led and standardized.
5. Can visits move into participants' homes under the same protocol and quality system?
Home visits should reduce travel for participants without adding a second set of standards. ICH E6(R3) Annex 2, which covers trial activity at participants' homes and local healthcare settings, takes effect in the EU on January 15, 2027.
Our answer: we have delivered in-home study visits since 2015, in all 50 states, under the same quality system as our sites.
6. What will I see, and how often?
Visibility between monitoring visits helps a study team act on enrollment and visit issues while there is still time to change course.
Our answer: real-time visit tracking and reporting on 21 CFR Part 11-compliant eSource.